Actively Recruiting
Occurrence of Antibodies Cross-reacting With Autoantigens in Primary EBV Infection
Led by University Hospital, Basel, Switzerland · Updated on 2025-02-25
80
Participants Needed
1
Research Sites
267 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The aim of this study is to assess the occurrence of antibodies cross-reacting with autoantigens that have been detected in the context of SLE in patients with primary EBV infection over time compared to a control group. It is to establish a biobank of patients with primary EBV infection allowing to longitudinally analyze the immune response and its accompanying inflammatory processes with focus on the occurrence of antibodies cross-reacting with autoantigens associated with SLE and other autoimmune diseases. Substudies will analyze * characteristics of primary EBV infection patients treated with antibiotics in comparison to patients treated without antibiotics and outcomes of these treatment regimens (occurrence of acute complications such as peritonsillar abscess (PTA) or need for tonsillectomy, frequency of fatigue or symptoms associated with chronic fatigue syndrome). * Procalcitonin (PCT) concentrations in primary EBV infection compared to control patients with similar symptoms and its association with disease severity and local complications. * the occurrence of fatigue and symptoms associated with chronic fatigue syndrome 6 and 12 months after primary EBV infection.
CONDITIONS
Official Title
Occurrence of Antibodies Cross-reacting With Autoantigens in Primary EBV Infection
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Signed informed consent
- Confirmed primary EBV infection by a clinician with compatible symptoms (such as malaise, headache, fever, tonsillitis, pharyngitis, cervical lymph node enlargement) and lab findings (elevated lymphocytes, reactive lymphocytes, elevated liver enzymes)
- Serology showing primary EBV infection (anti-EBNA IgG negative and anti-VCA IgM positive, with or without anti-VCA IgG positive)
- For control group: signed informed consent and either upper respiratory tract infection symptoms or confirmed primary Cytomegalovirus (CMV) infection
You will not qualify if you...
- Suspicion or diagnosis of infectious mononucleosis in the control group
- Immunosuppression including primary or secondary immunodeficiency or treatment with immunosuppressive drugs equivalent to 10mg or more prednisone daily
- History of autoimmune diseases such as systemic lupus erythematosus or vasculitis
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
University Hospital Basel, Division of Internal Medicine
Basel, Switzerland, 4031
Actively Recruiting
Research Team
M
Michael Osthoff, PD Dr. med.
CONTACT
S
Samuel Etienne
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here